Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06150547 · ClinicalTrials.gov registry record

A Study of Metabolic Agents Following Brain Radiation

A clinical trial, sponsored by Mayo Clinic.

Completed
Registry status
5
Enrollment target

NCT06150547: Completed study, sponsored by Mayo Clinic.

NCT06150547 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT06150547 has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
5 participants
Enrollment target

Study Summary

This study is being done to determine if CEST magnetic resonance imaging (MRI) and FDG PET are feasible techniques to detect metabolic differences between tumor and brain in patients with a brain tumor.

Primary Outcome

Number of subjects in whom glutamate metabolite is detected and measurable via CEST MRI in tumor, brain, and/or the ventricular space.

Interventions

  • DIAGNOSTIC_TEST FDG Positron Emission Tomography
  • DIAGNOSTIC_TEST Chemical Exchange Saturation Transfer Magnetic Resonance Imaging

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2023-12-27
Est. Completion 2025-08-04
Mayo Clinic

2,844 total trials

What the finished NCT06150547 record still lists

NCT06150547 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 5 participants, a relatively small participant target.

The record links to 0 conditions, and to 2 interventions - of which FDG Positron Emission Tomography is the first listed.

NCT06150547 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06150547 about?

NCT06150547 is a clinical study titled "A Study of Metabolic Agents Following Brain Radiation". This study is being done to determine if CEST magnetic resonance imaging (MRI) and FDG PET are feasible techniques to detect metabolic differences between tumor and brain in patients with a brain tumor.

What is the current status of trial NCT06150547?

This trial is currently completed. The enrollment target is 5 participants. The study started on 2023-12-27. Estimated completion is 2025-08-04.

What interventions are being tested in trial NCT06150547?

The interventions under investigation include: FDG Positron Emission Tomography (DIAGNOSTIC_TEST), Chemical Exchange Saturation Transfer Magnetic Resonance Imaging (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT06150547?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06150547, the US trial registry maintained by the National Library of Medicine. NCT06150547 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.